Introducing APIs to Silicone and Controlling Elution Rates
Single-entity combination devices, which are therapies containing manufactured components that have both device and drug elements, have shown the potential to address some of the most challenging chronic conditions patients face today.
For this reason, drug-eluting devices and solid implant drug delivery platforms have seen a heavy focus in development of new therapies. This surge is particularly prevalent because of their potential to release controlled doses of drugs precisely and consistently to a treatment area over a long period of time.
This whitepaper reviews the methods for introducing an active pharmaceutical ingredient to raw silicone and explores a new means of controlling long-term elution rates. The paper also takes a closer look at each of these methods and presents test results proving the effectiveness of each.
